Benzinga

Benzinga

Benzinga

viernes, septiembre 04

ResMed Inc

RMDNYSE
Trade with Public
Trade with Public
$229.19
-1.68-0.73%
al cierre: Sep 3, 5:00 PM EST
$229.20
0.010%
After hour: 7:56 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

ResMed Financials

ResMed (RMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period
Benzinga Newsdesk

Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'

Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.
Tanya Rawat

PRO
ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.80 by 2.14 percent. This is a 20.68 percent increase over earnings of $2.37 per share from the same period
Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

Analysts Maintain Bull Case On ResMed Despite Competition Concerns

ResMed beat earnings and revenue estimates as sales rose 11% and margins expanded. Analysts backed long-term growth and raised price targets despite competition concerns.
Vandana Singh

Insights into ResMed Q2 Earnings

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved